VRAYLAR bipolar I depression safety

Most common adverse reactions (≥5% and at least twice that of placebo)1

Rates of somnolence and sedation in VRAYLAR 1.5 mg/day (7%) and 3 mg/day (6%) groups were similar to placebo (4%)1

>99% of EPS and akathisia events in
bipolar I depression studies
were mild or moderate2

*EPS included akinesia, drooling, dyskinesia, dystonia, extrapyramidal disorder, hypokinesia, muscle tightness, musculoskeletal stiffness, myoclonus, oculogyric crisis, salivary hypersecretion, tardive dyskinesia, and tremor.1

EPS=extrapyramidal symptoms.

Discontinuation rates1

Overall, 6% of the patients who received VRAYLAR discontinued treatment due to an adverse reaction, compared with 5% of placebo-treated patients in these trials.

Monitor patients when initiating or changing the dose of VRAYLAR.1

EPS and akathisia are among the most common adverse reactions and are most frequently observed upon initiation and up-titration.1,2

Most common sexual adverse reactions across clinical studies2

All sexual adverse reactions were reported to be mild to moderate in severity and did not appear to be dose-dependent2

Discontinuation rates1

Overall, 6% of the patients who received VRAYLAR discontinued treatment due to an adverse reaction, compared with 5% of placebo-treated patients in these trials.

Monitor patients when initiating or changing the dose of VRAYLAR.1

EPS and akathisia are among the most common adverse reactions and are most frequently observed upon initiation and up-titration.1,2

Most common sexual adverse reactions across clinical studies2